Type 2M:Milwaukee-1 von Willebrand disease: an in-frame deletion in the Cys509-Cys695 loop of the von Willebrand factor A1 domain causes deficient binding of von Willebrand factor to platelets
| Autor: | Pamela A. Christopherson, Robert R. Montgomery, Philip A. Kroner, Joan Cox Gill, David J. Mancuso, Elizabeth A. Vokac |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Von Willebrand factor type C domain
congenital hereditary and neonatal diseases and abnormalities Mutation biology Immunology Cell Biology Hematology medicine.disease_cause medicine.disease Biochemistry Molecular biology chemistry.chemical_compound Von Willebrand factor chemistry hemic and lymphatic diseases Hemostasis medicine Coagulopathy Von Willebrand disease biology.protein Platelet Ristocetin circulatory and respiratory physiology |
| Zdroj: | Blood. 88:2559-2568 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v88.7.2559.bloodjournal8872559 |
| Popis: | This report examines the genetic basis of a variant form of moderately severe von Willebrand disease (vWD) characterized by low plasma von Willebrand factor antigen (vWF:Ag) levels and normal multimerization, typical of type 1 vWD, but disproportionately-low agonist-mediated platelet-binding activity. We identified an in-frame deletion in vWF exon 28 in three generations of affected family members, who are heterozygous for this mutation. The deletion of nucleotides 4,173–4,205 results in the loss of amino acids Arg629-Gln639 in the Cys509-Cys695 loop of the A1 domain in mature vWF. The secreted mutant vWF showed a normal multimeric profile but did not bind to platelets in the presence of optimal concentrations of either ristocetin or botrocetin. The mutant vWF also failed to interact with heparin, and with vWF monoclonal antibody AvW3, which blocks the binding of vWF to GPlb. In addition, mutant vWF showed reduced secretion from transfected cells concomitant with increased intracellular levels. These results confirm that the deletion is the genetic defect responsible for the reduced interaction of vWF with platelets. We have designated this new variant type 2M:Milwaukee-1 vWD. Our analysis suggests that the potential frequency of this phenotype in individuals diagnosed with type 1 vWD is about 0.5%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|